Meeting Banner
Abstract #4721

Mapping hypoxia in brain tumors using GdDO3NI: validation with PET and IHC

Babak Moghadas1, Matthew Scarpelli2, Christopher Rock1, Alberto Fuentes2, Debbie Healey2, Chad Quarles2, and Vikram D Kodibagkar1
1Biomedical engineering, Arizona State University, Tempe, AZ, United States, 2Barrow Neurological Institute, Phoenix, AZ, United States

In this study we have used the hypoxia-targeting MRI contrast agent GdDO3NI, (a nitroimidazole-based T1 contrast agent) to image the development of hypoxia in the rodent brain tumors at two different sizes. Our results indicate a range of signal enhancements from 5-20% over baseline in the 9L tumor using GdDO3NI with clearance from contralateral brain and muscle tissue. Furthermore the GdDO3NI enhancement correlates with PET imaging using hypoxia targeting 18F-FMISO and immunohistochemistry based on pimonidazole. This study further demonstrates the utility of GdDO3NI in non-invasive imaging of tissue hypoxia with high resolution.

This abstract and the presentation materials are available to members only; a login is required.

Join Here